Dublin, Sept. 28, 2022 (GLOBE NEWSWIRE) -- The "Transfection Technologies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global transfection technologies market size reached US$ 992.8 Million in 2021. Looking forward, the publisher expects the market to reach US$ 1,619.7 Million by 2027, exhibiting a CAGR of 8.5% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Transfection technology refers to the process of artificially introducing nucleic acid, such as Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA) and oligonucleotides, into the cells. It is introduced using various physical, chemical and biological methods, which can assist in modifying certain properties of the cell. It involves various methods, including cotransfection, electroporation, cationic lipid transfection and in-vivo transfection. This process is commonly used for various genomic studies that include gene expression, screening, RNA interference and Vivo research, along with the bioproduction of viruses and proteins.
The increasing prevalence of cancer and various chronic lifestyle diseases is one of the key factors driving the growth of the market. Furthermore, widespread adoption of reagent-based methods is also providing a boost to the market growth. In comparison to the traditionally used techniques, reagent-based transfection is less complicated to administer and more cost-effective.
In line with this, instrument-based methods, such as biolistic technology, microinjection and laserfection, are also gaining immense traction across the globe. Various technological advancements in cell research and therapeutic discovery are acting as another major growth-inducing factor.
In line with this, research in gene transfer is majorly performed under in-vivo conditions for the development of novel therapeutic drugs and various other applications. Other factors, including increasing investments by both government and private organizations to develop large scale transfection facilities, along with extensive research and development (R&D) activities in the field of protein therapeutics, are projected to drive the market further.
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Bio-RAD Laboratories Inc., Lonza Group AG, Maxcyte Inc., Mirus Bio LLC, Polyplus Transfection, Promega Corporation, Roche Holding AG, Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., etc.
Key Questions Answered in This Report:
- How has the global transfection technologies market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What has been the impact of COVID-19 on the global transfection technologies market?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the transfection method?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the end-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global transfection technologies market and who are the key players?
- What is the degree of competition in the industry?
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Transfection Technologies Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product Type
6.1 Reagent
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Instrument
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Others
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Application
7.1 Therapeutic Delivery
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Bio-Medical Research
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Protein Production
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Transfection Method
8.1 Lipofection
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Eletroporation
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Nucleofection
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Cotransfection
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Cationic Lipid Transfection
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 In-Vivo Transfection
8.6.1 Market Trends
8.6.2 Market Forecast
8.7 Others
8.7.1 Market Trends
8.7.2 Market Forecast
9 Market Breakup by Technology
9.1 Physical Transfection
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Biochemical Based Transfection
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Viral-Vector Based Transfection
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by End-User
10.1 Research Centers and Academic Institutes
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Hospitals and Clinics
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Pharmaceutical and Biotechnology Companies
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Others
10.4.1 Market Trends
10.4.2 Market Forecast
11 Market Breakup by Region
12 SWOT Analysis
13 Value Chain Analysis
14 Porters Five Forces Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Agilent Technologies Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Bio-RAD Laboratories Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Lonza Group AG
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Maxcyte Inc.
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.3.3 Financials
15.3.5 Mirus Bio LLC
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.6 Polyplus Transfection
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.7 Promega Corporation
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.8 Roche Holding AG
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.9 Sigma-Aldrich Corporation
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.10 Thermo Fisher Scientific Inc.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/wy28x6
Attachment
